Description Change in (A) systolic blood pressure (SBP) and (B) diastolic blood pressure (DBP) for patients taking antihypertensive medications (angiotensin‐converting enzyme inhibitors, angiotensin receptor...
Article Title: Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus
Publication Title: The Journal of Clinical Hypertension

Add to Cart

Description Kaplan‐Meier plot of time to first osmotic diuresis–related adverse event (AE). PBO indicates placebo; CANA, canagliflozin.
Article Title: Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus
Publication Title: The Journal of Clinical Hypertension

Add to Cart

Description Change in (A) systolic blood pressure (SBP) and (B) diastolic blood pressure (DBP) for the overall population and for patients with SBP ≥140 mm Hg and DBP ≥90 mm Hg (last observation carried...
Article Title: Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus
Publication Title: The Journal of Clinical Hypertension

Add to Cart

Description Proportion of patients with baseline systolic blood pressure (SBP) ≥140 mm Hg reaching SBP targets (last observation carried forward [LOCF]). PBO indicates placebo; CANA, canagliflozin. Patients...
Article Title: Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus
Publication Title: The Journal of Clinical Hypertension

Add to Cart